22 results
Optimization of safety of risk stratification for outpatient treatment in pulmonary embolism, through randomization between Hestia approach with or without NT-proBNP measurement.
The primary objective of this study is to estimate the effect of endovascular treatment on overall functional outcome after acute ischemic stroke of less than six hour duration, in patients with a symptomatic anterior circulation IAO. The secondary…
The primary objective of the trial is to determine if ischemic stroke subjects with a baseline NIH Stroke Scale Score (NIHSSS] >= 10 (8-9 with positive CTA) treated with recombinant tissue plasminogen activator (rt-PA; [Alteplase recombinant…
Does a deep vein thrombosis coincide with changes in HDL protein composition? What are the effects of anticoagulant therapy on HDL protein composition during therapy and after discontinuation of therapy?
Primary objective:To determine the individual cardiovascular risk profile, using validated risk score screening methodologies (Framingham, PROCAM, Reynolds Risk Score and SCORE) in patients with VTE to evaluate how many patients are at risk for…
To assess the costs and effects of tailoring the duration of elastic compression stocking (ECS) therapy after deep vein thrombosis (DVT) to individual patients needs.
Primary Objectives:To (1) Assess the feasibility and tolerability of performing US and/or contrast-enhanced MRI in children with central venous catheters (CVCs) or peripherally inserted central catheters (PICC lines); (2) assess the accuracy of US…
We will study the effects of the proteins of the contact activation system in thrombus formation, embolization and degradation in several coagulation assays.
To investigate the potential of an interaction between 4 mg/kg sugammadex and aspirin on platelet aggregation using collagen-induced whole blood aggregometry in young healthy male volunteers.
We aim to evaluate the use of MRDTI in the diagnosis of acute proximal DVT, comparing the findings with CUS. To evaluate the outcome of patients with positive and negative MRDTI and CUS, clinical outcome after 3 months of follow-up will be measured…
The objective of this study is to determine the clinical efficacy of endovascular thrombolytic treatment (ET) as compared to standard treatment (any therapeutic heparin regimen) in patients with proven cerebral venous sinus thrombosis and a high…
Currently, no established risk factor profile for developing arterial cardiovascular events after an acute unprovoked PE exists and is carried out in general practice. The aim of our project is to prospectively study the relation between presence…
This pilot is meaned to obtain:- experience and understanding in the presence of new embolic load in the brain by means of DW-MRI- Understanding in the number of patients in which probably the post-operative DW-MRI can not be done according to…
Primary Objective: To assess the relative risk of deep vein thrombosis associated with periodontal disease.Secondary Objective(s): To detect the prevalence of periodontal disease in subjects with and without deep vein thrombosis thrombosis.
In this study, we will assess whether healthy men with high-normal serum CK display attenuated platelet aggregation, compared to those with low-normal serum CK.
The primary objective of this clinical controlled trial is to define the overall effect of adenocorticotropic hormone on coagulation parameters in patients with primary adrenal insufficiency (as diagnosed by their physician by previous short ACTH…
To asses the comparability of the estimated dabigatran concentration in plasma via calibrated Hemoclot and the measured dabigatran concentrations assessed in a central lab in patients with moderate renal impairment undergoing primary unilateral…
2.1 Primary Objective• Evaluation of the levels of thrombophilic factors in the blood of HIV-infected patients before starting with cART and the changes of these levels when on cART for the time of one year. 2.2 Secondary Objective• Evaluation of…
To determine whether a dosing algorithm containing genetic information increases the time within therapeutic INR range during anticoagulation therapy with phenprocoumon compared to a dosing regimen that does not contain this genetic information.…
To determine whether a dosing algorithm containing genetic information increases the time within therapeutic INR range during anticoagulation therapy with acenocoumarol compared to a dosing regimen that does not contain this genetic information.…